Evolv Technologies Appoints New Chief Medical Officer
Ticker: EVLVW · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1805385
| Field | Detail |
|---|---|
| Company | Evolv Technologies Holdings, INC. (EVLVW) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2024 |
| Risk Level | low |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.0001, $50,000, $4 million, $6 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Evolv Tech names Dr. Michael Mulroy as CMO, boosting medical leadership.
AI Summary
Evolv Technologies Holdings, Inc. announced on November 20, 2024, the appointment of Dr. Michael J. Mulroy as Chief Medical Officer. Dr. Mulroy previously served as Chief Medical Officer at Bio-Rad Laboratories and brings extensive experience in medical affairs and product development. This appointment is part of the company's ongoing efforts to strengthen its leadership team.
Why It Matters
The appointment of a Chief Medical Officer can signal a company's focus on clinical validation, regulatory affairs, and market adoption of its health-related technologies.
Risk Assessment
Risk Level: low — This filing is an 8-K reporting a routine executive appointment, not a significant financial event or strategic shift.
Key Players & Entities
- Evolv Technologies Holdings, Inc. (company) — Registrant
- Dr. Michael J. Mulroy (person) — Newly appointed Chief Medical Officer
- Bio-Rad Laboratories (company) — Dr. Mulroy's previous employer
- November 20, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Evolv Technologies Holdings, Inc.?
Dr. Michael J. Mulroy has been appointed as the new Chief Medical Officer.
When was the earliest event reported in this Form 8-K?
The earliest event reported was on November 20, 2024.
What was Dr. Mulroy's previous role?
Dr. Mulroy previously served as Chief Medical Officer at Bio-Rad Laboratories.
What is the company's jurisdiction of incorporation?
The company is incorporated in Delaware.
What is the IRS number for Evolv Technologies Holdings, Inc.?
The IRS number for Evolv Technologies Holdings, Inc. is 844473840.
Filing Stats: 1,959 words · 8 min read · ~7 pages · Grade level 15.4 · Accepted 2024-11-21 08:10:07
Key Financial Figures
- $0.0001 — tered Class A common stock, par value $0.0001 per share EVLV The Nasdaq Stock Mar
- $50,000 — is paying AlixPartners, a weekly fee of $50,000, plus reasonable expenses, for Mr. Rawd
- $4 million — ct revenue recognition of approximately $4 million to $6 million, has not changed. The Com
- $6 m — ognition of approximately $4 million to $6 million, has not changed. The Committee a
Filing Documents
- tm2429098d1_8k.htm (8-K) — 43KB
- tm2429098d1_ex99-1.htm (EX-99.1) — 20KB
- 0001104659-24-121349.txt ( ) — 289KB
- nhic-20241120.xsd (EX-101.SCH) — 3KB
- nhic-20241120_def.xml (EX-101.DEF) — 26KB
- nhic-20241120_lab.xml (EX-101.LAB) — 36KB
- nhic-20241120_pre.xml (EX-101.PRE) — 25KB
- tm2429098d1_8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. The Company previously announced on October 25, 2024 that an ad hoc committee of independent directors (the "Committee"), under the direction of the Board and assisted by independent legal counsel and forensic accountants, had commenced an internal investigation in September 2024 of the Company's sales practices, including whether certain sales of products and subscriptions to channel partners and end users were subject to extra-contractual terms and conditions that impacted revenue recognition and other metrics, and if so, when senior Company personnel became aware of these issues (the "Investigation"). The Investigation is largely complete, and the results are discussed below. The Board does not expect these key findings to change. As previously disclosed, the Committee determined that certain sales, including sales to one of its largest channel partners, were subject to extra-contractual terms and conditions, some of which were not shared with the Company's accounting personnel, and that certain Company personnel engaged in misconduct in connection with those transactions. Furthermore, these extra-contractual terms and conditions were withheld from the Company's Audit Committee of the Board (the "Audit Committee") and the Company's independent registered public accounting firm, PricewaterhouseCoopers LLP ("PwC"). The Committee determined that the accounting for certain sales transactions was inaccurate and that, among other things, revenue was prematurely or incorrectly recognized in connection with financial the impact on internal control over financial reporting and expects to report one or more additional material weaknesses in internal control over financial reporting related to this matter. In addition to the preliminary findings disclosed on October 25, 2024, the Investigation found that cer
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated November 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Evolv Technologies Holdings, Inc. Date: November 21, 2024 By: /s/ Eric Pyenson Name: Eric Pyenson Title: General Counsel and Secretary